KR20200098615A - 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체 - Google Patents

사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체 Download PDF

Info

Publication number
KR20200098615A
KR20200098615A KR1020207020090A KR20207020090A KR20200098615A KR 20200098615 A KR20200098615 A KR 20200098615A KR 1020207020090 A KR1020207020090 A KR 1020207020090A KR 20207020090 A KR20207020090 A KR 20207020090A KR 20200098615 A KR20200098615 A KR 20200098615A
Authority
KR
South Korea
Prior art keywords
lysine
ala
leu
gly
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207020090A
Other languages
English (en)
Korean (ko)
Inventor
레이몬드 슈흐
키아라 인디아니
Original Assignee
콘트라펙트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘트라펙트 코포레이션 filed Critical 콘트라펙트 코포레이션
Publication of KR20200098615A publication Critical patent/KR20200098615A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207020090A 2017-12-12 2018-12-12 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체 Ceased KR20200098615A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762597577P 2017-12-12 2017-12-12
US62/597,577 2017-12-12
US201862721969P 2018-08-23 2018-08-23
US62/721,969 2018-08-23
PCT/US2018/065265 WO2019118632A1 (en) 2017-12-12 2018-12-12 Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
KR20200098615A true KR20200098615A (ko) 2020-08-20

Family

ID=66819724

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020090A Ceased KR20200098615A (ko) 2017-12-12 2018-12-12 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체

Country Status (11)

Country Link
US (1) US12121568B2 (cg-RX-API-DMAC7.html)
EP (1) EP3723789A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021506769A (cg-RX-API-DMAC7.html)
KR (1) KR20200098615A (cg-RX-API-DMAC7.html)
CN (1) CN111971058A (cg-RX-API-DMAC7.html)
AU (1) AU2018384790C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020011433A2 (cg-RX-API-DMAC7.html)
CA (1) CA3085644A1 (cg-RX-API-DMAC7.html)
IL (2) IL275060B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020006098A (cg-RX-API-DMAC7.html)
WO (1) WO2019118632A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020011433A2 (pt) 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
US20210062137A1 (en) * 2017-12-22 2021-03-04 The Rockefeller University Recombinant pseudomonas aeruginosa lysins
US10988520B2 (en) * 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation POLYPEPTIDE CONSTRUCTS WITH LYSINE ANTIMICROBIAL PEPTIDE (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREOF AND USES THEREOF
MX2021012166A (es) * 2019-04-05 2021-11-03 Contrafect Corp Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
KR102225240B1 (ko) * 2019-07-03 2021-03-10 경북대학교 산학협력단 다제내성 병원성 세균을 효과적으로 사멸시키는 재조합 항균 단백질 Ablysin의 용도
JP2023502940A (ja) * 2019-11-14 2023-01-26 コントラフェクト コーポレイション 溶解素-抗微生物ペプチド(amp)ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用
US20250324979A1 (en) * 2021-09-03 2025-10-23 Alexandre Ismail LysECD7 VARIANTS AND METHODS OF USING THE SAME
CN114410670B (zh) * 2022-01-29 2024-01-23 福建医科大学附属口腔医院 一种溶菌酶及其在口腔护理用品中的应用
CN117660413B (zh) * 2023-12-15 2024-06-07 华南理工大学 一种内溶素Lys009及其工程改造和应用
CN120173923B (zh) * 2025-05-08 2026-06-30 浙江大学 与PeiR裂解酶高维特征同源的产甲烷菌裂解酶及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
ES2761835T3 (es) 2009-02-06 2020-05-21 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Fagos antibacterianos, péptidos de fagos y métodos de uso de los mismos
WO2011060920A2 (en) * 2009-11-18 2011-05-26 Basf Plant Science Company Gmbh Process for the production of fine chemicals
DK2563916T3 (en) * 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
MX383544B (es) 2011-04-21 2025-03-14 Univ Rockefeller Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas
WO2015070912A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
BR112016030580B1 (pt) 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
ES2934714T3 (es) 2015-09-17 2023-02-24 Contrafect Corp Polipéptidos de lisina activos contra bacterias Gram-negativas
BR112020011433A2 (pt) 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
CN108103050A (zh) 2018-02-11 2018-06-01 中国医药集团总公司四川抗菌素工业研究所 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3840771A4 (en) 2018-08-23 2023-04-19 Contrafect Corporation POLYPEPTIDE CONSTRUCTS WITH LYSINE ANTIMICROBIAL PEPTIDE (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREOF AND USES THEREOF

Also Published As

Publication number Publication date
BR112020011433A2 (pt) 2020-12-01
IL303122A (en) 2023-07-01
IL275060B1 (en) 2023-06-01
MX2020006098A (es) 2020-08-24
AU2018384790A1 (en) 2020-07-30
US20210085758A1 (en) 2021-03-25
RU2020118691A (ru) 2022-01-13
IL275060A (en) 2020-07-30
JP2021506769A (ja) 2021-02-22
IL275060B2 (en) 2023-10-01
AU2018384790B2 (en) 2024-10-17
CN111971058A (zh) 2020-11-20
EP3723789A4 (en) 2021-12-01
EP3723789A1 (en) 2020-10-21
US12121568B2 (en) 2024-10-22
JP2024010053A (ja) 2024-01-23
WO2019118632A1 (en) 2019-06-20
CA3085644A1 (en) 2019-06-20
AU2018384790C1 (en) 2025-05-01
JP7646237B2 (ja) 2025-03-17

Similar Documents

Publication Publication Date Title
JP7646237B2 (ja) シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定
JP7684695B2 (ja) グラム陰性菌に対して活性を有する溶解素ポリペプチド
US20240018192A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US20220402984A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
KR20210049023A (ko) 리신-항미생물 펩타이드(amp) 폴리펩타이드 작제물, 리신, 이를 인코딩하는 단리된 폴리뉴클레오타이드 및 이의 용도
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
JP2021513865A (ja) 修飾PlySs2溶解素及びその使用
KR20210148320A (ko) 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체
KR20230162045A (ko) 그램-음성 박테리아에 대해 활성인 아무린, 리신, 및 리신-항미생물 펩타이드 (amp) 작제물
US20220411473A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
RU2807688C2 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
EP3873917A1 (en) Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601